Vycor Medical Inc (OTCQB: VYCO) is an early-stage medical device company that sells medical devices and generates revenue through product sales supported by a direct sales commission structure. The company reported selling, general and administrative expenses of $1,457,723 in FY2025, including sales commissions of $292,670, reflecting a transactional revenue model reliant on commissioned sales activity. Vycor trades on the OTCQB market under the symbol VYCO, where its common stock has been quoted since July 20, 2009. As of March 31, 2026, the company had 33,372,796 shares of common stock outstanding and approximately 126 stockholders of record. The company carries notes payable to both related and unrelated parties, accrued interest obligations, and an SBA EIDL loan, indicating a debt-dependent capital structure. Vycor has never paid a cash dividend and does not anticipate doing so. The company reported a net loss of $72,426 in FY2025, an improvement from a net loss of $107,200 in FY2024. A portion of operations has been wound down and is reported as discontinued operations.

Revenue model

Transactional product sales of medical devices, supported by commissioned sales. Sales commissions totaled $292,670 in FY2025, down $18,870 from FY2024 (per 10-K filed 2026-03-31).

Products and services

Medical devices. Specific product names are not identified in the available filing excerpts.

Customers and end markets

Customer types and end markets are not identified in the available filing excerpts.

Value-chain role

Medical device manufacturer and seller. The company holds inventory, records trade accounts receivable, and incurs cost of goods sold, indicating it sells physical products directly.

Geographic exposure

Geographic breakdown is not specified in the available filing excerpts. The filing references a foreign currency translation adjustment line item, suggesting some non-U.S. activity, but no specific markets are identified.

Source: SEC 10-K, filed 2026-03-31

Industry: Surgical & Medical Instruments & Apparatus Peers: E Med Future, Inc. Arch Therapeutics, Inc. CHEMBIO DIAGNOSTICS, INC. Rapid Therapeutic Science Laboratories, Inc. PROCYON CORP Sharps Technology Inc